Parathyroid Hormone (PTH) Homeostasis in Bartter Syndrome
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Parathyroid hormone (PTH) gland calcium sensing receptor (CASR) regulates PTH secretion. CASR is also expressed in nephron thick ascending limb (TAL). Bartter syndrome (BS), a normotensive hypokalemic tubulopathy, may be due to mutations in different TAL channels, including the potassium channel ROMK. Mutations in CASR may also cause BS through its effects on ROMK function. However, it is unknown whether ROMK mutations exert any effects on CASR function and PTH physiology. Preliminary data from our center shows that PTH levels were specifically elevated in type II (where ROMK is mutated) and not in type IV (where another gene, Barttin is defective) BS, without a common explanation. We assume that the mutation in ROMK may cause a dysregulation of PTH secretion via possible interaction with CASR.
The purpose of this study is: to investigate the PT-gland function and regulation in BS.
Methods: Patients with BS type II and IV and normal controls will undergo a standard protocol of controlled ionic hypo- and hypercalcemia, during which PTH secretion, phosphate balance and calcium excretion will be followed. Calcium Vs PTH response curves will be generated and compared.
Expected impact and benefit: the results of this study will help understand the mechanisms of PTH regulation beyond CASR.
| Condition |
|---|
|
Hypocalcemia Hypercalcemia |
| Study Type: | Observational |
| Study Design: | Observational Model: Case Control Time Perspective: Prospective |
| Official Title: | Case-control Study of the PTH Homeostasis in Adolescents and Young Adults With Bartter Syndrome |
Serum and urine will be later analyzed for FGF-23 and other key molecules in PTH homeostasis.
| Estimated Enrollment: | 15 |
| Study Start Date: | January 2013 |
| Estimated Study Completion Date: | June 2014 |
| Estimated Primary Completion Date: | December 2013 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
Type II BS
Adolescents and young adults with type II Bartter syndrome
|
|
Type IV BS
Adolescents and adults with type IV Bartter syndrome
|
|
Controls
Age and sex- matched controls
|
Show Detailed Description Eligibility| Ages Eligible for Study: | 14 Years to 35 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
Adolescent and young adult patients with Bartter syndrome and age- and sex- matched controls.
Inclusion Criteria:
- Bartter syndrome
- Normal Vitamin D status
Exclusion Criteria:
- Age < 14 yrs
Contacts and Locations| Israel | |
| Soroka University medical Center | Not yet recruiting |
| Beer Sheva, Israel, 84101 | |
| Contact: Daniel Landau, MD 972-8-6400546 ldaniel@bgu.ac.il | |
| Contact: Ruth Schreiber, MD 972-8-6400546 ruthalon@rogers.com | |
| Principal Investigator: Daniel Landau, MD | |
| Sub-Investigator: Ruth Schreiber, MD | |
More Information
No publications provided
| Responsible Party: | Daniel Landau MD, Head, Pediatrics Department A and Pediatric Nephrology Service, Soroka University Medical Center |
| ClinicalTrials.gov Identifier: | NCT01021280 History of Changes |
| Other Study ID Numbers: | Sor492809ctil |
| Study First Received: | November 25, 2009 |
| Last Updated: | June 13, 2012 |
| Health Authority: | Israel: Ministry of Health |
Keywords provided by Soroka University Medical Center:
|
Bartter syndrome, parathyroid hormone, calcium sensing receptor, |
ROMK channel Barttin gene PTH response to hypo- and hypercalcemia |
Additional relevant MeSH terms:
|
Bartter Syndrome Hypercalcemia Hypocalcemia Renal Tubular Transport, Inborn Errors Kidney Diseases Urologic Diseases Hyperaldosteronism |
Adrenocortical Hyperfunction Adrenal Gland Diseases Endocrine System Diseases Calcium Metabolism Disorders Metabolic Diseases Water-Electrolyte Imbalance |
ClinicalTrials.gov processed this record on June 17, 2013